Sarepta Therapeutics, Inc.
SRPT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.34 | 0.60 | -0.29 | 0.63 |
| FCF Yield | -2.96% | -6.60% | -3.15% | -6.58% |
| EV / EBITDA | 37.24 | -21.77 | -20.17 | -20.02 |
| Quality | ||||
| ROIC | 6.06% | -9.80% | -21.24% | -16.95% |
| Gross Margin | 83.22% | 87.91% | 85.00% | 86.17% |
| Cash Conversion Ratio | -0.87 | 0.93 | 0.46 | 1.06 |
| Growth | ||||
| Revenue 3-Year CAGR | 26.80% | 21.00% | 19.99% | 22.61% |
| Free Cash Flow Growth | 41.74% | -64.53% | 25.76% | -2,006.52% |
| Safety | ||||
| Net Debt / EBITDA | 0.76 | -2.13 | -1.09 | 3.03 |
| Interest Coverage | 11.86 | -12.17 | -10.07 | -7.24 |
| Efficiency | ||||
| Inventory Turnover | 0.43 | 0.47 | 0.69 | 0.52 |
| Cash Conversion Cycle | 737.24 | 511.73 | 384.18 | 501.55 |